Elizabeth Buck - 15 Sep 2021 Form 3 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Chief Scientific Officer
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol
BDTX
Transactions as of
15 Sep 2021
Net transactions value
$0
Form type
3
Filing time
17 Sep 2021, 16:19:59 UTC
Next filing
17 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BDTX Common Stock 95,192 15 Sep 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BDTX Stock Option (Right to Buy) 15 Sep 2021 Common Stock 16,579 $0.7200 Direct F1
holding BDTX Stock Option (Right to Buy) 15 Sep 2021 Common Stock 8,289 $3.20 Direct F2
holding BDTX Stock Option (Right to Buy) 15 Sep 2021 Common Stock 74,714 $6.42 Direct F3
holding BDTX Stock Option (Right to Buy) 15 Sep 2021 Common Stock 22,382 $10.86 Direct F4
holding BDTX Stock Option (Right to Buy) 15 Sep 2021 Common Stock 29,842 $19.00 Direct F5
holding BDTX Stock Option (Right to Buy) 15 Sep 2021 Common Stock 50,000 $28.69 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option vested and became exercisable on September 13, 2019, with the remainder vesting in 36 equal monthly installments thereafter.
F2 25% of the shares subject to this option vested and became exercisable on December 11, 2019, with the remainder vesting in 36 equal monthly installments thereafter.
F3 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
F4 25% of the shares subject to this option vested and became exercisable on December 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
F5 25% of the shares subject to this option vested and became exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter.
F6 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

Exhibit 24 Power of Attorney